Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Java 26, due in March with structured concurrency, lazy constants, AOT object caching, and primitive types in patterns, instanceof, and switch, has entered a second rampdown phase for bug fixes. Java ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech announced plans to reduce its workforce by approximately 20% as part of a ...

What if machines could not only learn but also teach themselves to become better with each iteration? This isn’t the plot of a sci-fi movie—it’s the reality unfolding in artificial intelligence ...